Quantcast
Last updated on April 23, 2014 at 17:36 EDT

Latest CSL Behring Stories

2014-02-20 08:32:25

International study by CSL Behring is world's first placebo-controlled phase III trial to examine subcutaneous administration of C1-INH for use in treating rare, sometimes life-threatening, condition KING OF PRUSSIA, Pa., Feb. 20, 2014 /PRNewswire/ -- CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with frequent hereditary...

2013-12-13 20:22:10

New Kcentra Label Includes Urgent Reversal of Warfarin in an Emergency Surgery Setting KING OF PRUSSIA, Pa., Dec. 13, 2013 /PRNewswire/ -- CSL Behring today announced that Kcentra(®) (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication -- urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or...

2013-12-09 20:22:42

Data Presented at the American Society of Hematology (ASH) Annual Meeting NEW ORLEANS, Dec. 9, 2013 /PRNewswire/ -- Data presented today by CSL Behring at the 55th Annual Meeting of the American Society of Hematology (ASH) showed Kcentra(®) (Prothrombin Complex Concentrate [Human]) was superior to plasma, the current standard of care in the U.S., in adult patients taking vitamin K antagonist therapy (VKA; e.g., warfarin) who required warfarin reversal prior to an urgent surgery or...

2013-12-03 16:24:40

The global biopharmaceutical's latest corporate responsibility report offers a bird's- eye view of the company's economic, social and environmental performance. KING OF PRUSSIA, Pa., Dec. 3, 2013 /PRNewswire/ -- CSL Behring's parent company CSL Limited (ASX:CSL) reaffirms the companies' commitment to responsible business practice and sustainable development in its new corporate responsibility report - Our Corporate Responsibility 2013. The report details CSL's performance across key corporate...

2013-11-25 12:26:55

Alpha-1 is a Serious Medical Condition That Is Often Misdiagnosed as COPD or Asthma KING OF PRUSSIA, Pa., Nov. 25, 2013 /PRNewswire/ -- CSL Behring today announced the availability of DNA(1) Advanced Alpha-1 Screening(TM) (DNA(1)), a new test that aims to improve diagnosis of Alpha-1 Antitrypsin Deficiency (Alpha-1). Launched during Alpha-1 Awareness Month, DNA(1) is the only comprehensive Alpha-1 test available that identifies known and unknown clinically relevant genetic variants to help...

2013-11-18 16:25:59

DUBLIN, Ireland, November 18, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/r7jrwx/global_markets) has announced the addition of the "Global Markets For Specialty Surgical Wound Care Products In 2013: Surgical Sealants, Glues, Absorbable Hemostats, And Adhesion Prevention Products" [http://www.researchandmarkets.com/research/r7jrwx/global_markets ] report to their offering. <start_newscom> (Logo:...

2013-11-11 16:23:30

DUBLIN, November 11, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/vbs28l/blood_banking_and) has announced the addition of the "Blood Banking And Blood Products - Global Strategic Business Report" [http://www.researchandmarkets.com/research/vbs28l/blood_banking_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report analyzes the worldwide markets for Blood Banking and Blood...

2013-11-08 16:23:41

DUBLIN, November 8, 2013 /PRNewswire/ -- Research and Markets(http://www.researchandmarkets.com/research/dmmswk/2013_deep) has announced the addition of the "2013 Deep Research Report on Global and China Human Coagulation Factor VIII Industry" [http://www.researchandmarkets.com/research/dmmswk/2013_deep ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This 2013 Deep Research Report is a professional and in-depth research...

2013-11-08 08:28:06

Responding HAE specialists agree that self-administration is advantageous to patients' time, independence and convenience BALTIMORE, Nov. 8, 2013 /PRNewswire/ -- More patients with hereditary angioedema (HAE), a rare and potentially fatal genetic disorder, are being offered and opting for self-administration therapy, according to data from a new survey being presented at the 2013 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Of the HAE treatment centers...

2013-10-24 23:27:17

DeepResearchReports offer “2013 Deep Research Report on China Human Albumin Market” in its vast china based database. The report provides market status and industry competition pattern. Dallas, Texas (PRWEB) October 24, 2013 This is a professional and depth research report on the China Human Albumin industry. The report provides a basic overview of the industry including definitions, applications and industry chain structure. It then introduced Human Albumin manufacturing...